You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR SECRETIN SYNTHETIC PORCINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for secretin synthetic porcine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00065962 ↗ Secretin for the Treatment of Autism Completed National Institute on Deafness and Other Communication Disorders (NIDCD) Phase 3 1999-06-01 Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00065962 ↗ Secretin for the Treatment of Autism Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1999-06-01 Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00620919 ↗ Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis Terminated Massachusetts General Hospital Phase 1 2008-02-01 1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Multidetector Computed Tomography (MDCT) of the pancreas. 2. To demonstrate that RG1068-enhanced MDCT improves image quality of the pancreas in patients with chronic pancreatitis. 3. To evaluate if RG1068 enhanced MDCT results in improved delineation of structural abnormalities of the pancreatic duct as compared to non-enhanced MDCT.
NCT00621283 ↗ Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population Terminated Massachusetts General Hospital Phase 1 2008-02-01 1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography. 2. To demonstrate that RG1068-enhanced MRCP improves image quality relative to unenhanced MRCP in patients with unexplained acute recurrent pancreatitis (ARP) and chronic pancreatitis. 3. To evaluate if the use of RG1068-enhanced MRCP improves structural delineation of the pancreatic duct as compared to the non-enhanced MRCP. 4. To assess pancreatic exocrine function by quantifying pancreatic fluid output into the duodenum and the apparent diffusion coefficient of the pancreas.
NCT00621556 ↗ Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas Terminated Massachusetts General Hospital Phase 1 2008-02-01 1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography 2. To demonstrate that RG1068-enhanced MRCP improves detection and characterization of intraductal papillary mucinous neoplasms (IPMN) relative to unenhanced MRCP in patients with suspected IPMN 3. To correlate findings on MRCP with histologically confirmed malignancy
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for secretin synthetic porcine

Condition Name

Condition Name for secretin synthetic porcine
Intervention Trials
Chronic Pancreatitis 2
Intraductal Papillary Mucinous Neoplasms 1
Acute Recurrent Pancreatitis 1
Autism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for secretin synthetic porcine
Intervention Trials
Pancreatitis, Chronic 2
Pancreatitis 2
Pancreatic Neoplasms 1
Pancreatic Intraductal Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for secretin synthetic porcine

Trials by Country

Trials by Country for secretin synthetic porcine
Location Trials
United States 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for secretin synthetic porcine
Location Trials
Massachusetts 3
Washington 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for secretin synthetic porcine

Clinical Trial Phase

Clinical Trial Phase for secretin synthetic porcine
Clinical Trial Phase Trials
Phase 3 1
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for secretin synthetic porcine
Clinical Trial Phase Trials
Terminated 3
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for secretin synthetic porcine

Sponsor Name

Sponsor Name for secretin synthetic porcine
Sponsor Trials
Massachusetts General Hospital 3
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 1
National Institute on Deafness and Other Communication Disorders (NIDCD) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for secretin synthetic porcine
Sponsor Trials
Other 3
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.